Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice
Pubblicato online: 13 apr 2022
Pagine: 415 - 425
Accettato: 20 set 2021
DOI: https://doi.org/10.2478/acph-2022-0022
Parole chiave
© 2022 Shihao Zhuang et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Respiratory syncytial virus (RSV) is the most common cause of small airways inflammation in the lungs (bronchiolitis) in neonates and immunocompromised adults. The deregulation of cellular and plasma components leads to increased morbidity and mortality. The activation of the clotting cascade plays a key role in the progression of disease severity during viral infection. The current investigation studied the effect of bivalirudin (BR) on the progression and cellular effects of RSV-induced infection in the neonatal mice model. Mice (5–7 days old) were inoculated intranasally with RSV with or without BR administration (2 mg kg−1 day−1,